Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
PHASE1
This study comprises a Dose Escalation phase followed by a Dose Expansion p...
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors
PHASE1
The purpose of this study is to test mirvetuximab soravtansine (IMGN853) in...
Status
Completed
Location
University of Kansas Medical Center Research Institute
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
PHASE2
IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plu...
A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting
N/A
Epithelial ovarian cancer, which includes fallopian tube and primary perito...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2026-06-30
Trial ID
NCT07687602
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
PHASE2
Ovarian cancer is a lethal disease with an estimated 310,000 new cases and ...
Status
Recruiting
Location
UC San Diego Health - Moores Cancer Center /ID# 277574
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
PHASE3
This is a Phase 3, open label, randomized study designed to compare the saf...
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
PHASE2
Cancer is a condition where cells in a specific part of body grow and repro...
Status
Recruiting
Location
University of Alabama at Birmingham (UAB) Hospital /ID# 274793